CY6463 (FORMERLY IW-6463)

A Phase 2a pilot study evaluating IW-6463, a CNS-penetrant sGC stimulator, in individuals with MELAS

United Mitochondrial Disease Foundation (UMDF) Power Surge Conference (2020)

Chad Glasser PharmD MPH

This presentation details the rationale for the use of sGC stimulators in this patient population and describes the Phase 2a study design.

MELAS = mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like episode

Return to Archive